Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CCR5 | P51681 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603229 | 0.90 | MEN1 (0.63) | MEN1KMT2ACCR5POLBAPEX1 | |
| SCHEMBL13543040 | 0.90 | POLB (0.56) | MEN1KMT2ATACR1CCR5POLB | |
| SCHEMBL3940288 | 0.88 | TACR1 (0.64) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL3556747 | 0.86 | MEN1 (0.56) | MEN1KMT2ATACR1CCR5SLC6A4 | |
| SCHEMBL4027887 | 0.86 | L3MBTL1 (0.57) | MEN1KMT2ACCR5SLC6A4SLC6A2 | |
| SCHEMBL341156 | 0.85 | TACR1 (0.58) | TACR1POLBAPEX1TDP1SLC6A4 | |
| SCHEMBL4158712 | 0.84 | MEN1 (0.54) | MEN1KMT2ACCR5SLC6A4SLC6A2 | |
| SCHEMBL6701738 | 0.83 | CCR5 (0.55) | MEN1KMT2ATACR1CCR5POLB | |
| SCHEMBL13543041 | 0.83 | SMN1; SMN2 (0.57) | MEN1KMT2ATACR1CCR5POLB | |
| SCHEMBL2769377 | 0.83 | KCNH2 (0.61) | MEN1KMT2ACCR5KCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | AQUINO CHRISTOPHER JOSEPH | 2009-02-26 | — | — | US | disclosed |
| US-7452992-B2 | inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS); 1-((1R,5S)-8-{2-[3-(2,2-dimethylpropanoyl)-6-phenyl-1,3-oxazinan-6-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-20040122049-A1 | Novel piperidine derivatives as modulators of chemokine receptor | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1383744-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR | AstraZeneca AB (SE) | 2004-01-28 | — | — | EP | disclosed |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| EP-1373205-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| CN-1441781-A | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AG (SE) | 2003-09-10 | — | — | CN | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002079156-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002076948-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053172-A1 | HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR1 | MEN1 4508/4885KMT2A 4579/4885TACR1 148/4885 |
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | MEN1 4785/4885KMT2A 4756/4885TACR1 43/4885 |
| US-20040122049-A1 | Novel piperidine derivatives as modulators of chemokine receptor | CCR5, CCR2, CXCR1 | MEN1 4819/4885KMT2A 4575/4885TACR1 31/4885 |
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CXCR1 | MEN1 4812/4885KMT2A 4403/4885TACR1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.